| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
T-1105 (T1105), an analog of T-705 (favipiravir), is a novel and potent broad-spectrum antiviral inhibitor that inhibits the polymerases of RNA viruses after being converted to the actiive form: ribonucleoside triphosphate (RTP) metabolite. T-1105 has a broad spectrum of antiviral activity against various RNA viruses, including Zika virus (ZIKV), influenza virus, arenaviruses, bunyaviruses, West Nile virus (WNV), yellow fever virus (YFV), and foot-and-mouth disease virus (FMDV).
| Targets |
parainfluenza-3 virus（EC50= 17 μM）;Punta Toro virus（EC50= 24 μM）;ZIKV strain SZ01（EC50= 97.5 μM）
|
|---|---|
| ln Vitro |
Zika virus (ZIKV), influenza virus, arenaviruses, bunyaviruses, West Nile virus (WNV), yellow fever virus (YFV), foot-and-mouth disease virus (FMDV), and other RNA viruses are all susceptible to T-1105's antiviral activity[1][2].
T-1105 exhibits strong anti-RNA virus activity against the parainfluenza-3 virus and the Punta Toro virus in MDCK cells, with EC50 values of 17 μM and 24 μM, respectively[3]. One possible inhibitor of the Zika virus's replication is T-1105[4]. T-1105 does not affect cell viability at concentrations of 0–3 μM, but it can inhibit SFTSV replication in Vero cells with an IC50 of 49 μM[5]. |
| ln Vivo |
T-1105 (200 mg/kg, twice day for 6 days) effectively prevents the virus from replicating in infected pigs[6].
|
| Cell Assay |
Cell Line: Vero cells
Concentration: 0-3 μM Incubation Time: 4 h Result: Did not affect cell viability in the test range (0-3 μM). |
| Animal Protocol |
Animal Model: Pigs[6]
Dosage: 200 mg/kg Administration: Oral, 200 mg/kg, twice daily for 6 days Result: decreased viremia and elevated anti-FMD antibody titers, but no clinical indications of FMD were seen. |
| References |
|
| Molecular Formula |
C5H5N3O2
|
|---|---|
| Molecular Weight |
139.114
|
| Exact Mass |
139.038
|
| Elemental Analysis |
C, 43.17; H, 3.62; N, 30.21; O, 23.00
|
| CAS # |
55321-99-8
|
| Related CAS # |
Favipiravir;259793-96-9
|
| PubChem CID |
294642
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
640.8±55.0 °C at 760 mmHg
|
| Melting Point |
ca 270℃
|
| Flash Point |
341.3±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.634
|
| LogP |
0.32
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
241
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=NC=CN=C1O)N
|
| InChi Key |
SZPBAPFUXAADQV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H5N3O2/c6-4(9)3-5(10)8-2-1-7-3/h1-2H,(H2,6,9)(H,8,10)
|
| Chemical Name |
3-oxo-3,4-dihydropyrazine-2-carboxamide
|
| Synonyms |
T 1105; T1105.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~179.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (17.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (17.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (17.97 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1886 mL | 35.9428 mL | 71.8856 mL | |
| 5 mM | 1.4377 mL | 7.1886 mL | 14.3771 mL | |
| 10 mM | 0.7189 mL | 3.5943 mL | 7.1886 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
